Page 73 - Read Online

Lee et al. J Cancer Metastasis Treat 2021;7:27 https://dx.doi.org/10.20517/2394-4722.2021.58 Page 13 of 18

review. We regret not being able to cite the work published by many others due to the limitation of length.
Graphics programs available from BioRender.com were used by the authors to design and create Figure 1.

Authors’ contributions
Conception and design: Lee WK, Cheng SY
Writing, review, and revision: Lee WK, Cheng SY

Availability of data and materials
No applicable.

Financial support and sponsorship
Our research was supported by the Intramural Research Program of the Center for Cancer Research,
National Cancer Institute, National Institutes of Health (ZIA BC 011191).

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
©The Author(s) 2021.

REFERENCES
1. Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell 2017;168:629-43. DOI PubMed PMC
2. Franco HL, Kraus WL. No driver behind the wheel? Cell 2015;163:28-30. DOI PubMed
3. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45. DOI
PubMed
4. Lin CY, Lovén J, Rahl PB, et al. Transcriptional Amplification in tumor cells with elevated c-Myc. Cell 2012;151:56-67. DOI
PubMed PMC
5. Luo Z, Lin C, Guest E, et al. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity
and transcriptional output. Mol Cell Biol 2012;32:2608-17. DOI PubMed PMC
6. Wang Y, Zhang T, Kwiatkowski N, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell
2015;163:174-86. DOI PubMed PMC
7. Zanconato F, Battilana G, Forcato M, et al. Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. Nat
Med 2018;24:1599-610. DOI PubMed PMC
8. Zeng M, Kwiatkowski NP, Zhang T, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and
CDK12/13. Elife 2018;7:e39030. DOI PubMed PMC
9. Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature
2014;511:616-20. DOI PubMed PMC
10. Christensen CL, Kwiatkowski N, Abraham BJ, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent
CDK7 inhibitor. Cancer cell 2014;26:909-22. DOI PubMed PMC
11. Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat
Rev Endocrinol 2017;13:644-60. DOI PubMed
12. Lee WK, Lee J, Kim H, et al. Peripheral location and infiltrative margin predict invasive features of papillary thyroid
microcarcinoma. Eur J Endocrinol 2019;181:139-49. DOI PubMed
13. Choi JB, Lee WK, Lee SG, et al. Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of
clinically apparent lymph node metastasis: a large retrospective analysis of 5,348 patients. Cancer Manag Res 2018;10:2883-91. DOI
PubMed PMC
14. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for
differentiated and anaplastic thyroid cancer: what changed and why? Thyroid 2017;27:751-6. DOI PubMed PMC
15. Ferrari SM, Elia G, Ragusa F, et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020;9:S28-42. DOI PubMed
PMC
16. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid
cancer. Thyroid 2012;22:1104-39. DOI PubMed